News
Public · Published
SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus
Sellas Life Sciences, ImmunityBio and Iovance Biotherapeutics ended October lower, falling 43%, 21% and 12%, respectively, compared with a 1.1% decline in the SPDR S&P Biotech ETF. Merck and AstraZeneca earnings calls highlighted cancer-vaccine programs and emerging competition in cancer treatment.
Published:
Updated:
What happened
Sellas Life Sciences, ImmunityBio and Iovance Biotherapeutics ended October lower, falling 43%, 21% and 12%, respectively, compared with a 1.1% decline in the SPDR S&P Biotech ETF. Merck and AstraZeneca earnings calls highlighted cancer-vaccine programs and emerging competition in cancer treatment.
Confirmed
Global impact / market context
New treatments could challenge the cancer markets targeted by Iovance and ImmunityBio, potentially affecting future sales if competing therapies gain adoption. Merck’s comments on vaccine trials and an improved lung-cancer study therefore matter to investors weighing these companies’ growth prospects against clinical and commercial competition.
Analyst inference
The three biotechnology stocks fell more than the broad biotech ETF during October, while the article links attention to Merck and AstraZeneca’s cancer strategies and retail buyout hopes. The reported figures show relative weakness, but the article does not establish what caused each stock’s decline.
Analyst inference
What to watch
- Watch for further results from Merck’s vaccine and Keytruda combination studies; the reported improvement in progression-free survival means patients lived longer without disease worsening in that study. Confirmed
- AstraZeneca’s partnership combines antibody-drug conjugates, medicines that deliver cancer-killing drugs to tumors, with Ivonescimab; further detail could clarify the treatment strategy. Confirmed
- Track whether competing cancer treatments progress toward routine use, since stronger alternatives could pressure future sales expectations for Iovance and ImmunityBio; the article provides no launch dates. Analyst inference
Affected assets
- OP — Optimism